TY - JOUR
T1 - Mandibulofacial dysostosis with microcephaly
T2 - Mutation and database update
AU - Care4Rare Canada Consortium
AU - UCLA Clinical Genomics Center
AU - Huang, Lijia
AU - Vanstone, Megan R.
AU - Hartley, Taila
AU - Osmond, Matthew
AU - Barrowman, Nick
AU - Allanson, Judith
AU - Baker, Laura
AU - Dabir, Tabib A.
AU - Dipple, Katrina M.
AU - Dobyns, William B.
AU - Estrella, Jane
AU - Faghfoury, Hanna
AU - Favaro, Francine P.
AU - Goel, Himanshu
AU - Gregersen, Pernille A.
AU - Gripp, Karen W.
AU - Grix, Art
AU - Guion-Almeida, Maria Leine
AU - Harr, Margaret H.
AU - Hudson, Cindy
AU - Hunter, Alasdair G.W.
AU - Johnson, John
AU - Joss, Shelagh K.
AU - Kimball, Amy
AU - Kini, Usha
AU - Kline, Antonie D.
AU - Lauzon, Julie
AU - Lildballe, Dorte L.
AU - López-González, Vanesa
AU - Martinezmoles, Johanna
AU - Meldrum, Cliff
AU - Mirzaa, Ghayda M.
AU - Morel, Chantal F.
AU - Morton, Jenny E.V.
AU - Pyle, Louise C.
AU - Quintero-Rivera, Fabiola
AU - Richer, Julie
AU - Scheuerle, Angela E.
AU - Schönewolf-Greulich, Bitten
AU - Shears, Deborah J.
AU - Silver, Josh
AU - Smith, Amanda C.
AU - Temple, I. Karen
AU - van de Kamp, Jiddeke M.
AU - van Dijk, Fleur S.
AU - Vandersteen, Anthony M.
AU - White, Sue M.
AU - Zackai, Elaine H.
AU - Zou, Ruobing
AU - Bulman, Dennis E.
N1 - Funding Information:
Additional Supporting Information may be found in the online version of this article. ∗Correspondence to: Matthew Lines, Metabolics, 3rd floor Max Keeping Wing, Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada. E-mail: mlines@cheo.on.ca Contract grant sponsors: Genome Canada; the Canadian Institutes of Health Research; the Ontario Genomics Institute; Ontario Research Fund; Genome Quebec; Children’s Hospital of Eastern Ontario Foundation; Resident Research Award from Physician’s Services Incorporated (PSI) Foundation.
Funding Information:
The authors gratefully acknowledge the participation of the study participants and their families, without whom this work would not be possible. We thank Dr. Mark J. Stephan for his contribution to this work. We thank UCLA Clinical Genomics Center for their assistance with recruiting two of the individuals in this study.
Publisher Copyright:
© 2015 Wiley Periodicals, Inc.
PY - 2016/2
Y1 - 2016/2
N2 - Mandibulofacial dysostosis with microcephaly (MFDM) is a multiple malformation syndrome comprising microcephaly, craniofacial anomalies, hearing loss, dysmorphic features, and, in some cases, esophageal atresia. Haploinsufficiency of a spliceosomal GTPase, U5–116 kDa/EFTUD2, is responsible. Here, we review the molecular basis of MFDM in the 69 individuals described to date, and report mutations in 38 new individuals, bringing the total number of reported individuals to 107 individuals from 94 kindreds. Pathogenic EFTUD2 variants comprise 76 distinct mutations and seven microdeletions. Among point mutations, missense substitutions are infrequent (14 out of 76; 18%) relative to stopgain (29 out of 76; 38%), and splicing (33 out of 76; 43%) mutations. Where known, mutation origin was de novo in 48 out of 64 individuals (75%), dominantly inherited in 12 out of 64 (19%), and due to proven germline mosaicism in four out of 64 (6%). Highly penetrant clinical features include, microcephaly, first and second arch craniofacial malformations, and hearing loss; esophageal atresia is present in an estimated ~27%. Microcephaly is virtually universal in childhood, with some adults exhibiting late “catch-up” growth and normocephaly at maturity. Occasionally reported anomalies, include vestibular and ossicular malformations, reduced mouth opening, atrophy of cerebral white matter, structural brain malformations, and epibulbar dermoid. All reported EFTUD2 mutations can be found in the EFTUD2 mutation database.
AB - Mandibulofacial dysostosis with microcephaly (MFDM) is a multiple malformation syndrome comprising microcephaly, craniofacial anomalies, hearing loss, dysmorphic features, and, in some cases, esophageal atresia. Haploinsufficiency of a spliceosomal GTPase, U5–116 kDa/EFTUD2, is responsible. Here, we review the molecular basis of MFDM in the 69 individuals described to date, and report mutations in 38 new individuals, bringing the total number of reported individuals to 107 individuals from 94 kindreds. Pathogenic EFTUD2 variants comprise 76 distinct mutations and seven microdeletions. Among point mutations, missense substitutions are infrequent (14 out of 76; 18%) relative to stopgain (29 out of 76; 38%), and splicing (33 out of 76; 43%) mutations. Where known, mutation origin was de novo in 48 out of 64 individuals (75%), dominantly inherited in 12 out of 64 (19%), and due to proven germline mosaicism in four out of 64 (6%). Highly penetrant clinical features include, microcephaly, first and second arch craniofacial malformations, and hearing loss; esophageal atresia is present in an estimated ~27%. Microcephaly is virtually universal in childhood, with some adults exhibiting late “catch-up” growth and normocephaly at maturity. Occasionally reported anomalies, include vestibular and ossicular malformations, reduced mouth opening, atrophy of cerebral white matter, structural brain malformations, and epibulbar dermoid. All reported EFTUD2 mutations can be found in the EFTUD2 mutation database.
KW - EFTUD2
KW - MFDM
KW - Mandibulofacial dysostosis
KW - Mandibulofacial dysostosis Guion-Almeida type
KW - Mandibulofacial dysostosis with microcephaly
KW - Microcephaly
UR - http://www.scopus.com/inward/record.url?scp=84961600155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961600155&partnerID=8YFLogxK
U2 - 10.1002/humu.22924
DO - 10.1002/humu.22924
M3 - Article
C2 - 26507355
AN - SCOPUS:84961600155
SN - 1059-7794
VL - 37
SP - 148
EP - 154
JO - Human mutation
JF - Human mutation
IS - 2
ER -